The immune system in cancer metastasis: friend or foe?

Metastatic disease is the leading cause of death among cancer patients and involves a complex and inefficient process. Every step of the metastatic process can be rate limiting and is influenced by non-malignant host cells interacting with the tumor cell. Over a century ago, experiments first indicated a link between the immune system and metastasis. This phenomenon, called concomitant immunity, indicates that the primary tumor induces an immune response, which may not be sufficient to destroy the primary tumor, but prevents the growth of a secondary tumor or metastases. Since that time, many different immune cells have been shown to play a role in both inhibiting and promoting metastatic disease. Here we review classic and new observations, describing the links between the immune system and metastasis that inform the development of cancer therapies.

[1]  C. Galmarini,et al.  Concomitant resistance and early-breast cancer: should we change treatment strategies? , 2013, Cancer and Metastasis Reviews.

[2]  J. Oppenheim,et al.  Alarmins and Antitumor Immunity. , 2016, Clinical therapeutics.

[3]  H. Putter,et al.  NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study , 2012, BMC Cancer.

[4]  M. Miyazaki,et al.  Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. , 2009, European journal of cancer.

[5]  T. Hagemann,et al.  Tumour-associated macrophages and cancer. , 2013, Current opinion in pharmacology.

[6]  D. Xie,et al.  TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. , 2012, Cancer cell.

[7]  J. Pollard,et al.  Immune cell promotion of metastasis , 2015, Nature Reviews Immunology.

[8]  J. Pollard,et al.  Macrophages regulate the angiogenic switch in a mouse model of breast cancer. , 2006, Cancer research.

[9]  J. Remack,et al.  ICAM-2 Expression Mediates a Membrane-Actin Link, Confers a Nonmetastatic Phenotype and Reflects Favorable Tumor Stage or Histology in Neuroblastoma , 2008, PloS one.

[10]  R. Ruggiero,et al.  A serum-mediated mechanism for concomitant resistance shared by immunogenic and non-immunogenic murine tumours. , 1996, British Journal of Cancer.

[11]  L. Lanier,et al.  Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[13]  E. Alici,et al.  Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity , 2015, Front. Immunol..

[14]  L. Zitvogel,et al.  Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer , 2012, Oncoimmunology.

[15]  T. Nomura,et al.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in self-tolerance and autoimmune disease. , 2006, Current topics in microbiology and immunology.

[16]  H. Friess,et al.  Desmoplastic Reaction Influences Pancreatic Cancer Growth Behavior , 2004, World Journal of Surgery.

[17]  W. Zou,et al.  Regulatory T-cell compartmentalization and trafficking. , 2006, Blood.

[18]  R. Azevedo,et al.  T Cells Induce Pre-Metastatic Osteolytic Disease and Help Bone Metastases Establishment in a Mouse Model of Metastatic Breast Cancer , 2013, PloS one.

[19]  Alexandre Corthay,et al.  Does the Immune System Naturally Protect Against Cancer? , 2014, Front. Immunol..

[20]  N. Mukaida,et al.  High-dose cyclophosphamide induces specific tumor immunity with concomitant recruitment of LAMP1/CD107a-expressing CD4-positive T cells into tumor sites. , 2015, Cancer letters.

[21]  I. Holen,et al.  Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis , 2014, Bone.

[22]  S. Karpatkin,et al.  Role of Platelets, Thrombin, Integrin llb-llla, Fibronectin and Von Willebrand Factor on Tumor Adhesion in Vitro and Metastasis in Vivo , 1995, Thrombosis and Haemostasis.

[23]  M. Yashiro,et al.  ICAM-2 Gene Therapy for Peritoneal Dissemination of Scirrhous Gastric Carcinoma , 2004, Clinical Cancer Research.

[24]  H. Komatsu [Antibody therapy in cancer]. , 2010, Nihon rinsho. Japanese journal of clinical medicine.

[25]  R. North,et al.  T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites , 1977, The Journal of experimental medicine.

[26]  M. Shibuya,et al.  MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. , 2002, Cancer cell.

[27]  R. Ruggiero,et al.  Concomitant tumor resistance: the role of tyrosine isomers in the mechanisms of metastases control. , 2012, Cancer research.

[28]  M. Toda,et al.  Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. , 1998, International immunology.

[29]  Lewis L Lanier,et al.  Natural killer cells and cancer. , 2003, Advances in cancer research.

[30]  Hongwei Liang,et al.  Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance , 2014, Front. Immunol..

[31]  Zhiwei Hu,et al.  Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. , 2007, Blood.

[32]  L. Coussens,et al.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. , 2009, Cancer cell.

[33]  I. Ellis,et al.  Upregulation of MICA on high-grade invasive operable breast carcinoma. , 2007, Cancer immunity.

[34]  E. Gorelik Concomitant tumor immunity and the resistance to a second tumor challenge. , 1983, Advances in cancer research.

[35]  Georg Krupitza,et al.  Initial steps of metastasis: Cell invasion and endothelial transmigration , 2011, Mutation research.

[36]  D. Bowtell,et al.  Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. , 2012, Cancer research.

[37]  K. Steimer,et al.  Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine. , 1992, The Journal of general virology.

[38]  S. Briest,et al.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. , 2009, Cancer research.

[39]  J. Peterse,et al.  Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.

[40]  R. Kerbel,et al.  Mouse models of advanced spontaneous metastasis for experimental therapeutics , 2011, Nature Reviews Cancer.

[41]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[42]  W. Schatten An experimental study of postoperative tumor metastases. I. Growth of pulmonary metastases following total removal of primary leg tumor , 1958, Cancer.

[43]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[44]  M. Liu,et al.  Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors. , 1998, Cancer research.

[45]  A. Möller,et al.  Hypoxia-driven immunosuppression contributes to the pre-metastatic niche , 2013, Oncoimmunology.

[46]  C. Janeway Immunobiology: The Immune System in Health and Disease , 1996 .

[47]  J. Erler,et al.  Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. , 2009, Cancer cell.

[48]  Lucas H. Horan,et al.  Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. , 2014, The Journal of clinical investigation.

[49]  G. Cheng,et al.  Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. , 2009, Cancer cell.

[50]  M. A. Curotto de Lafaille,et al.  Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? , 2009, Immunity.

[51]  E. E. Tyzzer Factors in the Production and Growth of tumor Metastases. , 1913, The Journal of medical research.

[52]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo , 2005 .

[53]  A. Ben-Baruch Organ selectivity in metastasis: regulation by chemokines and their receptors , 2007, Clinical & Experimental Metastasis.

[54]  P. Dalerba,et al.  Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction , 2002, Immunological reviews.

[55]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[56]  Y. Kimura,et al.  Resveratrol Prevents Tumor Growth and Metastasis by Inhibiting Lymphangiogenesis and M2 Macrophage Activation and Differentiation in Tumor-associated Macrophages , 2016, Nutrition and cancer.

[57]  J. Schlom,et al.  Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity , 2011, Experimental biology and medicine.

[58]  S. Bu,et al.  N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cells , 2013, BMC Cancer.

[59]  Cyrus M. Ghajar,et al.  Circulating and disseminated tumor cells: harbingers or initiators of metastasis? , 2017, Molecular oncology.

[60]  E. R. Kasala,et al.  Natural killer cells: the journey from puzzles in biology to treatment of cancer. , 2015, Cancer letters.

[61]  Benjamin G. Gowen,et al.  A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection , 2015, Science.

[62]  H. Wiley,et al.  Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo , 2013, Oncogene.

[63]  Wei Wu,et al.  Tumor-derived CD4+CD25+ Tregs inhibit the maturation and antigen-presenting function of dendritic cells. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[64]  J. Trowsdale,et al.  ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients , 2010, International journal of cancer.

[65]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[66]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[67]  P. Reitsma,et al.  Tissue factor associates with survival and regulates tumour progression in osteosarcoma , 2016, Thrombosis and Haemostasis.

[68]  J. Blay,et al.  CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner , 2005, The Journal of experimental medicine.

[69]  A. Puisieux,et al.  Metastasis: a question of life or death , 2006, Nature Reviews Cancer.

[70]  O. Joffre,et al.  Cross-presentation by dendritic cells , 2012, Nature Reviews Immunology.

[71]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[72]  Z. Ballas,et al.  Role of NK Cell Subsets in Organ-Specific Murine Melanoma Metastasis , 2013, PloS one.

[73]  M. Smyth,et al.  NKG2D function protects the host from tumor initiation , 2005, The Journal of experimental medicine.

[74]  E. Dye The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells. , 1986, Journal of immunology.

[75]  J. Berzofsky,et al.  Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway , 2014, Cancer Immunology Research.

[76]  I. Ellis,et al.  Expression of the stress‐related MHC class I chain‐related protein MICA is an indicator of good prognosis in colorectal cancer patients , 2006, International journal of cancer.

[77]  R. Robison,et al.  Macrophage Polarization and Its Role in Cancer , 2015 .

[78]  R. Muschel,et al.  Coagulation and metastasis: what does the experimental literature tell us? , 2013, British journal of haematology.

[79]  Jinghang Zhang,et al.  CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.

[80]  I. Fidler,et al.  Metastasis: Quantitative Analysis of Distribution and Fate of Tumor Emboli Labeled With 125I-5-Iodo-2′ -deoxyuridine , 1970 .

[81]  N. Kawashima,et al.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[82]  M. Smyth,et al.  Immune surveillance of tumors. , 2007, The Journal of clinical investigation.

[83]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[84]  J. Sosman,et al.  Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy , 2013, Cancer Immunology Research.

[85]  Bethan Psaila,et al.  The metastatic niche: adapting the foreign soil , 2009, Nature Reviews Cancer.

[86]  W. Gorczyca,et al.  Complement C 5 a receptor facilitates cancer metastasis by altering T cell responses in the metastatic niche , 2014 .

[87]  Y. Kawakami,et al.  The mechanisms of cancer immunoescape and development of overcoming strategies , 2011, International journal of hematology.

[88]  J. Pollard,et al.  A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors , 2004, Cancer Research.

[89]  I. Svane,et al.  Increase of Circulating CD4+CD25highFoxp3+ Regulatory T Cells in Patients With Metastatic Renal Cell Carcinoma During Treatment With Dendritic Cell Vaccination and Low-Dose Interleukin-2 , 2010, Journal of immunotherapy.

[90]  F. Balkwill The significance of cancer cell expression of the chemokine receptor CXCR4. , 2004, Seminars in cancer biology.

[91]  Sharad K Sharma,et al.  Pulmonary Alveolar Macrophages Contribute to the Premetastatic Niche by Suppressing Antitumor T Cell Responses in the Lungs , 2015, The Journal of Immunology.

[92]  J. Bubeník Tumour MHC class I downregulation and immunotherapy (Review). , 2003, Oncology reports.

[93]  K. Arihiro,et al.  FOXP3 expression of micrometastasis-positive sentinel nodes in breast cancer patients. , 2009, Oncology reports.

[94]  K. Khazaie,et al.  Regulation of COX2 Expression in Mouse Mammary Tumor Cells Controls Bone Metastasis and PGE2-Induction of Regulatory T Cell Migration , 2012, PloS one.

[95]  E. Shevach Regulatory T cells in autoimmmunity*. , 2000, Annual review of immunology.

[96]  R. Jain,et al.  Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. , 2011, Cancer cell.

[97]  M. Bissell,et al.  Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. , 2006, Annual review of cell and developmental biology.

[98]  Ruud H. Brakenhoff,et al.  Dissecting the metastatic cascade , 2004, Nature Reviews Cancer.

[99]  T. Hembrough,et al.  Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. , 2003, Cancer research.

[100]  Tom C. Freeman,et al.  Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation , 2014, Immunity.

[101]  J. Niederkorn,et al.  Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge. , 1983, Journal of immunology.

[102]  C. Yee,et al.  The Effect of Radiation on the Immune Response to Cancers , 2014, International journal of molecular sciences.

[103]  J. Schlom,et al.  Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination , 2011, Cancer Immunology, Immunotherapy.

[104]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[105]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[106]  V. Vetvicka,et al.  Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18). , 1997, Journal of immunology.

[107]  T. Schumacher,et al.  T-cell-receptor gene therapy , 2002, Nature Reviews Immunology.

[108]  S. Deodhar,et al.  Role of preoperative irradiation in prolonging concomitant immunity and preventing metastasis in mice , 1971, Cancer.

[109]  J. Degen,et al.  Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. , 2005, Blood.

[110]  J. Blay,et al.  CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. , 2016 .

[111]  J. Abastado,et al.  Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. , 2010, The Journal of clinical investigation.

[112]  Paul J Hertzog,et al.  Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape , 2012, Nature Medicine.

[113]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[114]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[115]  A. Hesketh,et al.  The Macrophage Inhibitor CNI-1493 Blocks Metastasis in a Mouse Model of Ewing Sarcoma through Inhibition of Extravasation , 2015, PloS one.

[116]  M. Erkan Understanding the stroma of pancreatic cancer: co‐evolution of the microenvironment with epithelial carcinogenesis , 2013, The Journal of pathology.

[117]  J. Jonkers,et al.  IL17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis , 2015, Nature.

[118]  Tyzzer Ee,et al.  Factors in the Production and Growth of tumor Metastases. , 1913 .

[119]  A. Zlotnik New insights on the role of CXCR4 in cancer metastasis , 2008, The Journal of pathology.

[120]  A. Houghton,et al.  Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.

[121]  G. Hill,et al.  CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis , 2011, Proceedings of the National Academy of Sciences.

[122]  A. Cerwenka,et al.  NKG2D ligands in tumor immunity , 2008, Oncogene.

[123]  A. Harris,et al.  Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. , 1996, Cancer research.

[124]  C. Higano,et al.  Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. , 2013, The Journal of clinical investigation.

[125]  J. Mann,et al.  The role of pancreatic stellate cells in pancreatic cancer. , 2015, Surgical oncology.

[126]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[127]  R. Ruggiero,et al.  "Concomitant immunity" in murine tumours of non-detectable immunogenicity. , 1985, British Journal of Cancer.

[128]  S. Quezada,et al.  Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies , 2009, The Journal of experimental medicine.

[129]  J. Wolchok,et al.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.

[130]  S. Coffelt,et al.  Systemic inflammation: Cancer's long-distance reach to maximize metastasis , 2016, Oncoimmunology.